The investigate relationship between severe neutropenia and ABCB1 and ABCG2 gene polymorphisms with esophageal cancer patients receiving docetaxel, cisplatin and 5-fluorouracil chemotherapy

被引：0
|
作者：
Nomura, H. [1 ]
Tsuji, D. [2 ]
Demachi, K. [1 ]
Suzuki, S. [1 ]
Mochizuki, N. [1 ]
Yano, T. [3 ]
Daiko, H. [4 ]
Fujii, S. [5 ]
Kojima, T. [6 ]
Ito, K. [2 ]
Yamaguchi, M. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Pharm, Kashiwa, Chiba, Japan
[2] Univ Shizuoka, Clin Phrmacol & Genet, Shizuoka, Japan
[3] Natl Canc Ctr Hosp East, Endoscopy Div, Gastroenterol, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr Hosp, Esophageal Surg, Chuo, Japan
[5] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Pathol, Kashiwa, Chiba, Japan
[6] Natl Canc Ctr Hosp East, Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1590P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Febrile neutropenia in patients with esophageal cancer receiving combination chemotherapy of docetaxel, cisplatin, and 5-fluorouracil
    Nomura, H.
    Hatogai, K.
    Suzuki, S.
    Maki, Y.
    Mochizuki, N.
    Tanaka, M.
    Kojima, T.
    Saito, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S247 - S247
  • [2] ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
    Hisanaga Nomura
    Daiki Tsuji
    Ken Demachi
    Nobuo Mochizuki
    Haruki Matsuzawa
    Tomonori Yano
    Hiroyuki Daiko
    Satoshi Fujii
    Takashi Kojima
    Kunihiko Itoh
    Toshikatsu Kawasaki
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 315 - 324
  • [3] ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
    Nomura, Hisanaga
    Tsuji, Daiki
    Demachi, Ken
    Mochizuki, Nobuo
    Matsuzawa, Haruki
    Yano, Tomonori
    Daiko, Hiroyuki
    Fujii, Satoshi
    Kojima, Takashi
    Itoh, Kunihiko
    Kawasaki, Toshikatsu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 315 - 324
  • [4] Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy
    Ikeda, Midori
    Tsuji, Daiki
    Yamamoto, Keisuke
    Kim, Yong-Il
    Daimon, Takashi
    Iwabe, Yutaro
    Hatori, Masahiro
    Makuta, Ryo
    Hayashi, Hideki
    Inoue, Kazuyuki
    Nakamichi, Hidenori
    Shiokawa, Mitsuru
    Itoh, Kunihiko
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (02) : 149 - 153
  • [5] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
    Tsuji, D.
    Yokoi, M.
    Suzuki, K.
    Daimon, T.
    Nakao, M.
    Ayuhara, H.
    Kogure, Y.
    Shibata, K.
    Hayashi, T.
    Hirai, K.
    Inoue, K.
    Hama, T.
    Takeda, K.
    Nishio, M.
    Itoh, K.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (05): : 435 - 440
  • [6] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study
    D Tsuji
    M Yokoi
    K Suzuki
    T Daimon
    M Nakao
    H Ayuhara
    Y Kogure
    K Shibata
    T Hayashi
    K Hirai
    K Inoue
    T Hama
    K Takeda
    M Nishio
    K Itoh
    The Pharmacogenomics Journal, 2017, 17 : 435 - 440
  • [7] Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients
    Yoshimoto, Takanori
    Oshima, Tadayuki
    Fukada, Takashi
    Imamura, Nobuko
    Nakanishi, Takashi
    Ebisutani, Nobuhiko
    Morishita, Daisuke
    Mieno, Masatoshi
    Nakai, Keisuke
    Sei, Hiroo
    Kitayama, Yoshitaka
    Eda, Hirotsugu
    Okugawa, Takuya
    Tomita, Toshihiko
    Fukui, Hirokazu
    Shinzaki, Shinichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 142 - 148
  • [8] Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients
    Takanori Yoshimoto
    Tadayuki Oshima
    Takashi Fukada
    Nobuko Imamura
    Takashi Nakanishi
    Nobuhiko Ebisutani
    Daisuke Morishita
    Masatoshi Mieno
    Keisuke Nakai
    Hiroo Sei
    Yoshitaka Kitayama
    Hirotsugu Eda
    Takuya Okugawa
    Toshihiko Tomita
    Hirokazu Fukui
    Shinichiro Shinzaki
    International Journal of Clinical Oncology, 2024, 29 : 142 - 148
  • [9] Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
    Nomura, Hisanaga
    Tsuji, Daiki
    Ueno, Shohei
    Kojima, Takashi
    Fujii, Satoshi
    Yano, Tomonori
    Daiko, Hiroyuki
    Demachi, Ken
    Itoh, Kunihiko
    Kawasaki, Toshikatsu
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 420 - 429
  • [10] Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
    Hisanaga Nomura
    Daiki Tsuji
    Shohei Ueno
    Takashi Kojima
    Satoshi Fujii
    Tomonori Yano
    Hiroyuki Daiko
    Ken Demachi
    Kunihiko Itoh
    Toshikatsu Kawasaki
    Investigational New Drugs, 2022, 40 : 420 - 429
12345